Inhibition of ovulation by an oral contraceptive containing 100 mu g levonorgestrel in combination with 20 mu g ethinylestradiol

被引:59
|
作者
Spona, J
Feichtinger, W
Kindermann, C
Wunsch, C
Brill, K
机构
[1] INST STERIL TREATMENT, VIENNA, AUSTRIA
[2] SCHERING AG, GERMAN DIV, D-1000 BERLIN, GERMANY
[3] FIRST DEPT OBSTET & GYNECOL, DIV MOL ENDOCRINOL, VIENNA, AUSTRIA
[4] LUDWIG BOLTZMANN INST EXPT ENDOCRINOL, DIV CELLULAR ENDOCRINOL, VIENNA, AUSTRIA
关键词
oral contraceptives; levonorgestrel; follicle growth;
D O I
10.1016/S0010-7824(96)00183-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Twenty-lour healthy female volunteers with normal ovulatory cycles, aged between 20 and 34 years (27.5 +/- 4.3), were included in a single-center, non-comparative study to investigate the effect on inhibition of ovulation of an oral contraceptive containing 20 mu g ethinylestradiol in combination with 100 mu g levonorgestrel. At baseline, during three treatment cycles and post-treatment, ultrasonography was used to examine the ovaries, to measure follicular size, and to measure the thickness of the endometrium. Serum levels of LH, FSH, estradiol, progesterone, total testosterone, free testosterone, SHBG, and CBG were also measured. Compared with treatment cycle 1, an increase in residual ovarian activity (follicle grades 4-5) was observed in cycles 2 and 3. Mean levels of LH, FSH, 17 beta-estradiol and progesterone remained suppressed during treatment. No escape ovulation was observed during the treatment phase of the study and there were no pregnancies. Ovulation was noted to return rapidly in the posttreatment cycle. Subjective and objective tolerance of the present regimen was noted to be good. Results indicate that the monophasic oral contraceptive containing 100 mu g levonorgestrel combined with 20 mu g ethinylestradiol effectively inhibits ovulation, providing adequate suppression of ovarian activity. (C) 1996 Elsevier Science Inc.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 50 条
  • [21] A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol
    Reisman, H
    Martin, D
    Gast, MJ
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (05) : S45 - S52
  • [22] Cycle control with oral contraceptives containing 20 μg of ethinyl estradiol -: A multicenter, randomized comparison of levonorgestrel ethinyl estradiol (100 μg/20 μg) and norethindrone ethinyl estradiol (1000 μg/20 μg)
    DelConte, A
    Loffer, F
    Grubb, GS
    CONTRACEPTION, 1999, 59 (03) : 187 - 193
  • [23] A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and levonorgestrel 30 μg daily
    Rice, CF
    Killick, SR
    Dieben, T
    Bennink, HC
    HUMAN REPRODUCTION, 1999, 14 (04) : 982 - 985
  • [24] Using a low-dose contraceptive in women 35 years of age and over:: 20 μg estradiol/100 μg levonorgestrel
    Carr, BR
    DelConte, A
    CONTRACEPTION, 2002, 65 (06) : 397 - 402
  • [25] SHORT-TERM AND LONG-TERM EFFECTS ON LIPID-METABOLISM OF ORAL-CONTRACEPTIVES CONTAINING 30 MU-G ETHINYLESTRADIOL AND 150 MU-G DESOGESTREL OR 3-KETO-DESOGESTREL
    KUHL, H
    JUNGHOFFMANN, C
    FITZNER, M
    MARZ, W
    GROSS, W
    HORMONE RESEARCH, 1995, 44 (03) : 121 - 125
  • [26] Effects on body weight and body composition of a low-dose oral estroprogestin containing ethinyl estradiol 20 μg plus levonorgestrel 100 μg
    Lello, Stefano
    Vittori, Giorgio
    Paoletti, Anna Maria
    Sorge, Roberto
    Guardianelli, Francesca
    Melis, Gian Benedetto
    GYNECOLOGICAL ENDOCRINOLOGY, 2007, 23 (11) : 632 - 637
  • [27] A 13-month multicenter clinical experience of a low-dose monophasic oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene in Latin American women
    Bassol, S
    Alvarado, G
    Arreola, RG
    Celis-Gonzalez, C
    Peña, EP
    Flores, JG
    Ahued, JR
    Ricalde, RL
    Lopez, CR
    Prieto, G
    Gurucharri, C
    Heredia, MG
    Ortiz, OC
    Percossi, G
    Casa, PRF
    Botto, E
    Tozzini, RI
    Botti, G
    de Pierro, AN
    Fernandez, M
    Lastreto, E
    Ñañez, M
    de Oliveira, HC
    Yazlle, MEDH
    Silva, J
    Calazar, G
    Gomez, J
    Penagos, G
    Cifuentes, R
    Torres, LA
    Reyes-Marquez, R
    Albrecht, G
    CONTRACEPTION, 2003, 67 (05) : 367 - 372
  • [28] The emerging use of the 20-μg oral contraceptive
    Poindexter, A
    FERTILITY AND STERILITY, 2001, 75 (03) : 457 - 465
  • [29] The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel
    Olsson, B
    Landgren, BM
    CLINICAL THERAPEUTICS, 2001, 23 (11) : 1876 - 1888
  • [30] Body weight change during use of a monophasic oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake
    Endrikat, J
    Gerlinger, C
    Cronin, M
    Wessel, J
    Ruebig, A
    Rosenbaum, P
    Düsterberg, B
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2001, 6 (04) : 199 - 204